T-Cell Lymphoma Market

Executive Summary

T-Cell Lymphoma Market was valued at US $1,729.36 million in 2021 and is projected to grow at 8.84% CAGR over the forecast period to reach US $2,875.01 million by 2027. T-Cell Lymphoma Market represented US $269.53 million opportunity over 2019-2021 and estimated to create US $1,145.65 million opportunity in 2027 over 2021.

T-Cell Lymphoma from Consainsights analyses the T-Cell Lymphoma Market in the Life Sciences industry over the forecast period to 2027.

T-Cell Lymphoma research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

T-Cell Lymphoma segmentation includes Type of Lymphoma, Type of Therapy and Geography.

Based on the Type of Lymphoma, the T-Cell Lymphoma analysis covers Peripheral T-cell Lymphoma, T-cell lymphoblastic lymphoma.

In Type of Lymphoma segment, Peripheral T-cell Lymphoma segment has highest cagr growth of 7.82%.

Based on the Type of Therapy, the T-Cell Lymphoma analysis covers Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Other Type of Therapy.

In Type of Therapy segment, Radiotherapy segment has highest cagr growth of 7.82%.

Based on the region, the T-Cell Lymphoma analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Mundipharma International, Bristol-Myers Squibb Company, Genmab A/S, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Autolus Therapeutics PLC, Acrotech Biopharma, Macopharma and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type of Lymphoma

Introduction

In 2021, Peripheral T-cell Lymphoma segment has the highest revenue of US $1,696.00 million and is expected to grow at CAGR of 7.82% by 2027 Peripheral T-cell Lymphoma segment has highest cagr growth of 7.82%.

Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma segment was valued at US $1,431.66 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $2,819.54 million by 2027. Peripheral T-cell Lymphoma segment represented US $264.33 million opportunity over 2019-2021 and estimated to create US $1,123.54 million opportunity in 2027 over 2021.

T-cell lymphoblastic lymphoma

T-cell lymphoblastic lymphoma segment was valued at US $28.17 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $55.47 million by 2027. T-cell lymphoblastic lymphoma segment represented US $5.20 million opportunity over 2019-2021 and estimated to create US $22.10 million opportunity in 2027 over 2021.

Type of Therapy

Introduction

In 2021, Radiotherapy segment has the highest revenue of US $676.52 million and is expected to grow at CAGR of 7.82% by 2027 Radiotherapy segment has highest cagr growth of 7.82%.

Radiotherapy

Radiotherapy segment was valued at US $571.08 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $1,124.69 million by 2027. Radiotherapy segment represented US $105.44 million opportunity over 2019-2021 and estimated to create US $448.17 million opportunity in 2027 over 2021.

Chemotherapy

Chemotherapy segment was valued at US $361.65 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $712.23 million by 2027. Chemotherapy segment represented US $66.77 million opportunity over 2019-2021 and estimated to create US $283.81 million opportunity in 2027 over 2021.

Immunotherapy

Immunotherapy segment was valued at US $302.48 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $595.70 million by 2027. Immunotherapy segment represented US $55.85 million opportunity over 2019-2021 and estimated to create US $237.38 million opportunity in 2027 over 2021.

Stem Cell Transplantation

Stem Cell Transplantation segment was valued at US $209.57 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $412.73 million by 2027. Stem Cell Transplantation segment represented US $38.69 million opportunity over 2019-2021 and estimated to create US $164.47 million opportunity in 2027 over 2021.

Other Type of Therapy

Other Type of Therapy segment was valued at US $15.06 million in 2019 and is projected to grow at 7.82% CAGR over the forecast period to reach US $29.66 million by 2027. Other Type of Therapy segment represented US $2.78 million opportunity over 2019-2021 and estimated to create US $11.82 million opportunity in 2027 over 2021.